Caspase-independent type III programmed cell death in chronic lymphocytic leukemia: the key role of the F-actin cytoskeleton by Barbier, Sardine et al.
haematologica | 2009; 94(4) | 507 | 
Original Article
Acknowledgments: we thank
Marcela Segade for 
proofreading.
Funding: this work was financed
by Fondation de France,
Ligue Contre le Cancer, and
Association pour la Recherche
sur le Cancer (contract n°
4043) (to SAS), as well as a
grant from the Canadian
Institute for Health and
Research (MOP-53152)
(to MS). S. Barbier was 
supported by a PhD fellowship
from MENRT. L. Chatre worked
in the group of M. Ricchetti,
Unité de Génétique Moléculaire
des Levures, Institut Pasteur.
Manuscript received July 21,
2008. Revised version arrived
November 20, 2008.
Manuscript accepted 
November 24, 2008.
Correspondence: 
Santos A. Susin. Centre de
Recherche des Cordeliers.
15, rue de l’Ecole de Médecine,
75006, Paris, France.
E-mail:
santos.susin@crc.jussieu.fr
Background
Programmed cell death has been traditionally related with caspase activation. However, it
is now accepted that caspase-independent forms of programmed cell death also regulate
cell death. In chronic lymphocytic leukemia, CD47 ligation induces one of these alternative
forms of cell death: type III programmed cell death. This poorly understood process is char-
acterized by cytoplasmic hallmarks, such as mitochondrial damage. To gain insights into
the molecular pathways regulating type III programmed cell death in chronic lymphocytic
leukemia, we performed extensive biochemical and cell biology assessments.
Design and Methods
After CD47 triggering, purified B-cells from 20 patients with chronic lymphocytic leukemia
were studied by flow cytometry, immunofluorescence and three-dimensional imaging,
immunoblotting, electron microscopy, and fibrillar/globular actin measurements. Finally,
we subjected CD47-treated chronic lymphocytic leukemia cells to a phagocytosis assay.
Results
We first confirmed that induction of type III programmed cell death is an efficient means
of triggering cell death in chronic lymphocytic leukemia. Further, we demonstrated that the
signaling events induced by CD47 ligation provoked a reduction in cell size. This alteration
is related to F-actin disruption, as the two other cytoskeleton networks, microtubules and
intermediate filaments, remain undisturbed in type III programmed cell death. Strikingly,
we revealed that the pharmacological modulation of F-actin dynamics regulated this type
of death. Finally, our data delineated a new programmed cell death pathway in chronic
lymphocytic leukemia initiated by CD47 triggering, and followed by serine protease acti-
vation, F-actin rearrangement, mitochondrial damage, phosphatidylserine exposure, and
cell clearance.
Conclusions
Our work reveals a key molecular tool in the modulation of cell death in chronic lympho-
cytic leukemia: F-actin. By assessing the regulation of F-actin and type III programmed cell
death, this analysis provides new options for destroying chronic lymphocytic leukemia
cells, such as a combination of therapies based on apoptosis regulators (e.g., caspases, Bcl-
2, Bax) along with alternative therapies based on type III death effectors (e.g., F-actin).
Key words: actin, apoptosis, caspase-independent cell death, CD47, chronic lymphocytic
leukemia, mitochondria.
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Introduction
Chronic lymphocytic leukemia (CLL) is characterized
by the accumulation of monoclonal B cells (CD20+, CD5+,
and CD23+) in the blood, bone marrow, and peripheral
lymphoid organs.1 This disease is the perfect example of a
human malignancy caused by an alteration in the ratio
between cell proliferation and programmed cell death
(PCD).2 In fact, CLL was initially considered as a disease
derived from an inherent defect in PCD.3 However, more
recent studies showed that the accumulation of leukemia
cells is a consequence of deregulation in both proliferation
and PCD.2,4 The elucidation of the molecular pathways
controlling PCD is, therefore, fundamental as it may pro-
vide new insights into understanding CLL physiopatholo-
gy. Additionally, a better knowledge of the molecular
mechanisms regulating cell death in CLL will help in the
design of effective treatments against this leukemia (e.g.,
providing new targets for the development of specific
PCD-based drugs).
In the last decade, the study of PCD focused on caspas-
es, a family of cysteine proteases specifically activated in
dying cells.5 Surprisingly, inhibition of caspases has in fact
revealed the existence of caspase-dependent and caspase-
independent cell death programs.6,7 As a consequence,
PCD is now classified into type I, type II, or type III.8-11
Type I PCD, or classical apoptosis, is caspase-depend-
ent5,12,13 and it can be triggered via death receptors along the
extrinsic pathway or via the mitochondrial intrinsic path-
way.14 Type II PCD is morphologically characterized by
the appearance of autophagic, double-membraned vac-
uoles.15,16 These cytoplasmic vesicles contain cellular
organelles, such as mitochondria or endoplasmic reticu-
lum.10 Type III PCD is the least well understood form of
death and occurs without pronounced nuclear chromatin
condensation.17,18 Type II and type III PCD are caspase-
independent.
The enormous amount of work performed to character-
ize type I PCD caspase-dependent apoptosis is related to
the fact that most of the currently available chemothera-
peutic agents kill tumor cells by triggering this kind of cell
death. However, because malignant CLL cells are distin-
guished by defects in the apoptotic type I PCD machinery
(e.g., p53 mutations, higher Bcl-2/Bax ratio) they can be
resistant to the cytotoxic action of these drugs.
Considering strategies to circumvent this resistance, an
important question emerged: is it possible to use alterna-
tive caspase-independent PCD pathways to modulate
PCD in CLL? The answer is, apparently, yes. In a recent
study, we reported that, after CD47-triggering, CLL cells
were efficiently killed by a caspase-independent type III
PCD program.17
CD47 antigen is a widely expressed glycoprotein com-
posed of a single IgV-like extracellular domain, a trans-
membrane region, and a short intracytoplasmic tail.19,20
Intense research on this receptor showed that ligation of
CD47 by immobilized specific monoclonal antibodies,
thrombospondin-1 (TSP-1), or a peptide derived from
TSP-1 (4N1K), induces PCD. The CD47-mediated type III
PCD pathway is characterized by impairment of the mito-
chondrial electron transport chain and exposure of phos-
phatidylserine on the outer leaflet of the plasma mem-
brane.17,21 Future goals in type III PCD/CLL research are
the identification of molecules/events reducing the life-
span of malignant B cells. This will be the basis for the
subsequent development of therapeutic agents modulat-
ing these factors to control pathological PCD.
In order to identify the key elements involved in type
III PCD, we conducted a multi-parametric biochemical
and cell biology assessment of purified B-cells from 20
patients with CLL. This assessment revealed that: (i) The
F-actin cytoskeleton is a key step in type III PCD; (ii)
Pharmacological modulation of F-actin microfilament
dynamics activated/abrogated this kind of death. F-actin
is, therefore, a target in the modulation of type III PCD in
CLL and seems to be an excellent candidate for the future
development of PCD-based drugs aimed at caspase-inde-
pendent cell death; (iii) Type III PCD is a good means of
inducing cell death in CLL. Indeed, contrary to type I cas-
pase-dependent PCD, the type III PCD program can be
engaged even in CLL cells with a high Bcl-2/Bax ratio.
Type III PCD could, therefore, overcome one of the most
important problems encountered in cells resistant to type
I PCD; (iv) CLL cells killed by type III PCD are efficiently
eliminated by macrophages. This kind of death is, there-
fore, an efficient pathway that allows for the physiologi-
cal elimination of dead cells; (v) Type III PCD is a highly
regulated pathway of cell death in CLL. This is an impor-
tant issue in the understanding of CLL biology. This death
pathway, initiated by CD47 triggering, is followed by ser-
ine protease activation, F-actin damage, ∆Ψm loss and
reactive oxygen (ROS) generation, phosphatidylserine
exposure in the outer leaflet of the plasma membrane, and
cell engulfment. 
Design and Methods
Patients, B-cell purification and culture conditions
After obtaining informed consent, peripheral blood was
collected from 20 CLL patients diagnosed according to
classical morphological and immunophenotypic criteria22
(Table 1). The Institutional Ethics Committee at Pitie-
Salpetriere Hospital approved this study. Mononuclear
cells were purified from blood samples using a standard
Ficoll-Hypaque gradient, and B cells were positively or
negatively selected by magnetic microbeads coupled
either to an anti-CD19 monoclonal antibody (positive
selection) or to anti-CD16, CD3, and CD14 monoclonal
antibodies (negative depletion) (Miltenyi Biotech). No
changes were found in the cell death response of positive-
ly or negatively selected cells. B-lymphocytes were cul-
tured in complete medium (RPMI 1640 supplemented
with 10% fetal calf serum, 2 mM L-glutamine, and 100
U/mL penicillin/streptomycin). Unless specified, reagents
were from Sigma-Aldrich.
Cell death induction and inhibition
To induce CD47-mediated cell death, cells were cul-
tured with soluble TSP-1 (20 µg/mL, Calbiochem) or on
pre-coated plates with CD47 monoclonal antibody (5
µg/mL, clone B6H12). In the indicated experiments, cells
were treated for 20 h with hydrocortisone (0.5 mM). For
inhibition assays, cytochalasin D, latrunculin A, nocoda-
zole, and colchicine were used at 5 µM, okadaïc acid was
used at 100 nM, TPCK at 20 µM, Q-VD.OPh (QVD) at 10
µM, and z-VAD.fmk, z-DEVD.fmk, z-LEHD.fmk, and z-
IETD.fmk at 50 µM.
Flow cytometry
We used 0.5 µM tetramethylrhodamineethylester
(TMRE, Invitrogen) for ∆Ψm assessment, 2 µM
hydroethidine (Invitrogen) for detection of reactive oxy-
gen species (ROS), annexin V-allophycocyanin (BD
Biosciences) to determine phosphatidylserine (PS) expo-
sure, and propidium iodide (0.5 µg/mL) to assess cell via-
bility. Chymotrypsin-like serine protease cytofluoromet-
ric detection was performed with a SerPaseTM kit from
Imgenex. Data analysis was carried out in a FACScalibur
(BD Biosciences) on the total cell population (10,000
cells).
Quantitative real-time reverse transcriptase 
polymerase chain reaction analysis
Total RNA from control or CLL cells was extracted with
Trizol reagent (Invitrogen) according to standard proce-
dures. Samples were examined in an ABI Prism 7000
sequence detector system with TaqManTM Assays-on-
demandTM Gene Expression Products (Applied Bio-
systems). Data were analyzed using the comparative Ct
method following the manufacturer’s protocol. The
amount of Bcl-2 and Bax mRNA measured in CLL cells
was normalized according to an endogenous reference
(the human 18S housekeeping gene) and relative to a cal-
ibrator (B cells from control donors).
Fibrillar and globular actin assessment
The fibrillar/globular-actin ratio (F-actin/G-actin ratio)
was determined by fluorometric assessment.23
Excitation/emission filters were 485/538 and 544/590 nm
for phalloidin-fluorescein isothiocyanate (F-actin, Sigma)
and DNase-Alexa 594 (G-actin, Molecular Probes),
respectively. One unit refers to the basal F-actin/G-actin
ratio measured in 106 untreated cells. All reactions were
recorded in a Fluoroskan AscentTM Fluorimeter (Thermo
Labsystems).
Phagocytosis assays
U937 monocytes were differentiated into macrophages
with 10 ng/mL phorbol 12-myristate 13-acetate (Calbio-
chem).24 Fluorescence microscopy assessment was per-
formed with macrophages seeded on glass coverslips, as
reported elsewhere.25 After incubation of macrophages
and JinB8 or CLL cells (3 h), coverslips were washed, fixed
in 4% PFA for 15 min and stained with Hoescht 33342
before image acquisition. For flow cytometry quantifica-
tion, macrophages were labeled with mouse monoclonal
anti-CD13-allophycocyanin antibody (BD Biosciences),
and JinB8 or CLL cells were labeled with 5 µM BODIPY®
FL C5-Ceramide (Molecular Probes) before the phagocyt-
ic meal. After 3 h of incubation, cells were analyzed and
phagocytosis was scored as the percentage of double-pos-
itive cells.
Protein extractions and immunoblot
Mitochondrial and cytosolic fractions were obtained
with the help of a kit from Pierce. Cell fractions were
lysed in 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1%
Triton X-100, and 1 mM EDTA. Protein content was
determined with the Bio-Rad DC kit and 30 mg of protein
were loaded for sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE). After blotting, PVDF fil-
ters were probed with anti Cox IV (Invitrogen), β-tubulin,
or Drp1 (BD Biosciences). All were detected using stan-
dard procedures.
Immunofluorescence and imaging
Cells were fixed with 4% PFA and stained for the detec-
tion of cytochrome c or Drp1 (BD Biosciences). Proteins
were detected according to standard procedures. The
quantification of different parameters by fluorescence
microscopy was performed in blind testing by at least
two investigators, on 150 cells for each data point, and
was repeated at least three times for different CLL
patients. Images were visualized in an Apotome-
equipped Zeiss Axioplan (Axiovert 200M, Zeiss) with an
Apochromat 100x/1.4 objective, acquired with a CCD
Roper Scientific Coolsnap HQ Camera, and analyzed
using Axiovision 4.4 software.
For actin, tubulin, and vimentin, imaging cells were
fixed with 4% PFA and maintained in liquid phosphate-
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Table 1. Patients’ characteristics. 
Patient# Age Gender Binet % IGVH % % Soluble
(yr) stage gene CD38 ZAP-70 CD23 
identity (ng/mL)
1 71 M A 91.8 9 14 47
2 62 M B 97.4 5 18 70
3 86 M C 99 9 19 633
4 67 M A 89 7 15 250
5 72 M A 89 2 10 75
6 85 F A 91 3 14 202
7 77 M A 94.8 9 18 41
8 91 F A 92.2 8 18 370
9 56 F A 94.7 5 11 121
10 76 M A 94 1 15 113
11 78 M A 92.4 41 40 233
12 75 M A 94 1 19 86
13 71 F A 92.6 5 14 190
14 89 F A 91.8 8 70 7.5
15 78 M B 92.6 9 14 77
16 80 F A 87.4 1 17 162
17 74 F A 97.1 7 63 168
18 84 F B 93 20 12 60
19 63 M B 97 9 19 66
20 60 M A 98.5 9 54 250
Gender: M: male; F: female.Binet stage: Binet stage of disease.% IGVH gene identity: IGVH
sequence homology compared with the closest germ line counterpart.The sequences with a
germ line homology of 98% or higher are normally considered unmutated and those with a
homology of less than 98% mutated.% CD38 and % ZAP-70: protein expression.CD38 and
ZAP-70 high expression levels are defined as more than 10% or 20% of positive cells, respec-
tively. Soluble CD23 levels are: controls: <10 ng/mL; stable disease: <70 ng/mL; progressive
disease: >70 ng/mL.
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buffered saline medium. After staining, cells were loaded
in an agar bed to preserve cell volume integrity. Analyses
were performed using an inverted laser-scanning confocal
microscope Zeiss Axiovert 200M with an Apochromat
100x/1.4 objective. Three-dimensional image acquisition
was done with a Z-stack on each 150 nm panel and three-
dimensional reconstruction was achieved using the Iso-
surface module of IMARIS software (Bitplane).
Fluorescence quantification was recorded using a single-
imaging frame collection and ImageJ 1.34-s software
(post-acquisition analysis).
Electron microscopy
Cells were fixed with 2% glutaraldehyde in phosphate
buffer (pH 7.4) for 2 h at room temperature, washed, and
post-fixed in 2% OsO4 before being embedded in
DurcupanTM. Analyses were performed as previously
described.17
Statistical analysis
The significance of differences between experimental
data was determined using Student’s t test for unpaired
observations.
Results
Phosphatidylserine exposure, mitochondrial damage,
serpase activation, and cell size reduction characterize
CD47-mediated type III programmed cell death 
in chronic lymphocytic leukemia cells
We previously reported that CD47 ligation by an immo-
bilized anti-CD47 monoclonal antibody, or by its natural
ligand, thrombospondin-1 (TSP-1), induces type III PCD in
CLL cells.17 This type of death, in which dynamin-related
protein-1 (Drp1) and mitochondria play key roles, is exclu-
sively characterized by cytoplasmic hallmarks. They
include exposure of PS in the outer leaflet of the plasma
membrane (Figure 1A), a decrease in mitochondrial trans-
membrane potential (∆Ψm; Figure 1B), and production of
reactive oxygen species (ROS) (Figure 1C).
Morphologically, type III PCD is not marked by signs of
nuclear condensation. In contrast, mitochondria undergo
striking morphological changes17 (Figure 1D). Through a
new confocal and cytofluorometric assessment we found
here that CD47 ligation provoked a significant reduction
in cell size (Figure 1E). Untreated CLL cells had a diameter
of around 6.585 ± 0.058 µm whereas after 1 h of treatment
with anti-CD47 monoclonal antibody the cells could be
distinguished into two groups. Cells in the first group (G1;
46% of cells) were of a similar size to untreated cells. The
second group (G2; 54% of the total population) showed a
10% decrease in cell diameter (5.656 ± 0.033 µm). The
percentage of smaller cells (G2 group) correlated strictly
with the percentage of cells showing PS exposure, ∆Ψm
loss, and ROS production after CD47 ligation (Figures 1A,
B, C, and E). Therefore, as has been described for other
types of cell death (e.g., type I PCD), our data revealed
that the reduction in cell size is a morphological hallmark
of type III PCD.
Type III PCD is considered to be caspase-independent
since the PS exposure induced by CD47 ligation is not pre-
vented by the presence of either broad or specific caspase
inhibitors (Figure 1F). In this way, the main effector cas-
pases, such as caspase-3, -7, or -9, remain inactive pro-
enzymes after CD47 triggering.17,21,25 In spite of this, type
III PCD specifically involves the activation of a family of
proteases: chymotrypsin-like serine proteases, a TPCK-
inhibitable family of proteases also named serpases
(Figure 1G).
Type III programmed cell death, an efficient
programmed cell death pathway in chronic 
lymphocytic leukemia
To give a more translational perspective to the above-
described approach, we analyzed the response of a panel
of CLL cells to CD47 triggering. Indeed, it seemed impor-
tant to know whether type III PCD is a general PCD path-
way in this form of leukemia. To this end, we first
assessed the response of B cells from 20 CLL patients to
CD47 ligation (see Table 1 for the patients’ characteris-
tics). These B cells have similar CD47 and Drp1 levels. In
addition, we analyzed the response of the same cells to
treatment with a typical type I caspase-dependent PCD
mediator, hydrocortisone. As depicted in Figure 1H, CLL
cells had a different response to type I and type III PCD
inducers and, when comparing CD47-mediated PCD and
hydrocortisone-induced apoptosis, CD47 ligation provid-
ed a more efficient means of inducing death in 50% of B
cells. In fact, our comparative analysis distinguished two
groups of CLL patients. In B cells from 10 patients (group
A in Figure 1H), the response to anti-CD47 monoclonal
antibody treatment was comparable to that in response to
hydrocortisone treatment. In contrast, CD47 ligation
appeared to be a more efficient means of inducing PCD in
B cells from the CLL patients in group B (Figure 1H,
patients # 2, 3, 6, 11, 14, 15, 17, 18, 19, and 20). 
To understand the different behavior in the response of
CLL cells to hydrocortisone-mediated type I PCD and
anti-CD47 monoclonal antibody-mediated type III PCD,
we assessed the levels of Bcl-2 and Bax mRNA transcripts
by quantitative polymerase chain reaction (Figure 1H,
right panel). The Bcl-2 family of proteins that regulates
type I PCD does not seem to be involved in the modula-
tion of type III PCD.17 It, therefore, seems plausible that
high ratios of anti-apoptotic Bcl-2/pro-apoptotic Bax pro-
teins regulate hydrocortisone-mediated apoptosis but not
anti-CD47 monoclonal antibody-mediated death. This
was indeed the case, as B cells displaying high Bcl-2/Bax
ratios (≥4.5; group B) were less responsive to hydrocorti-
sone. However, the Bcl-2/Bax ratio had no influence on
the response of CLL cells to anti-CD47 monoclonal anti-
body. These results revealed that, even in apoptotic type
I PCD resistant cells, it is possible to cause cell death
through the induction of type III PCD. It seems, there-
fore, that type III PCD is a general pathway in CLL. In
this sense, cells from the entire set of patients presented
signs of type III PCD, regardless of any prognostic differ-
ence. 
Overall, our assessment indicates that CD47-mediated
PCD could represent a good means of inducing PCD in
CLL. This is an important issue when considering this
type of cell death in the design of novel PCD-based
chemotherapeutic agents.
CD47-mediated programmed cell death involves 
a morphological alteration in the actin microfilament
network
The mitochondrial alterations characterizing type III
PCD (Figures 1B, C, and D)17 led us to extend our field of
study to the cytoskeleton. In fact, depolymerization or
cleavage of actin, cytokeratins, and other cytoskeletal
proteins have been incriminated in the alteration of mito-
chondrial function and morphology.13,26
Previous work showing that CD47-mediated PCD is
regulated by actin-associated proteins such as WASP,25
supports this view, as does the reduced size of cells treat-
ed with anti-CD47 monoclonal antibody (Figure 1E).
To determine whether the cytoskeleton was perturbed
in CD47-treated cells, we first investigated, through con-
focal imaging, the cellular distribution and the fluores-
cence intensity of the three known cytoskeleton net-
works: actin microfilaments, microtubules, and interme-
Cytoskeleton rearrangements in type III PCD
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Figure 1. CD47 ligation induces type III PCD. (A) Plasma membrane and cell viability alterations induced by CD47 monoclonal antibody
(mAb) ligation at different times. Chronic lymphocytic leukemia (CLL) cells were labeled with annexin V-APC and propidium iodide (PI).
Numbers reflect the percentage of annexin V+ and annexin V+/PI+ cells. (B) ∆Ψm dissipation provoked by CD47 mAb triggering in CLL
cells. After the indicated time, cells were labeled with TMRE. The percentages refer to cells with low ∆Ψm. (C) ROS production provoked
by CD47 mAb treatment at different times. CLL cells were labeled with HE, and the cells presenting ROS are shown as a percentage of
total cells. Experiments depicted in (A), (B), and (C) were carried out in the set of 20 CLL patients used in Figure 1H below, yielding lower
interexperimental variability (<5%). (D) Electron micrographs of CLL cells from a representative CLL donor, left untreated or incubated
with hydrocortisone (HC) (type I PCD positive control), TSP-1, or CD47 mAb (1 h). Right panels represent the typical mitochondrial mor-
phology observed after TSP-1 or CD47 mAb treatment. Bar = 1 µm. (E) Changes in cellular size induced by CD47 mAb treatment in CLL
cells measured by flow cytometry and immunofluorescence. In flow cytometry panels, the percentages refer to gated cells. FSC: Forward
Scatter; SSC: Side Scatter. Note that, after CD47 mAb-treatment, the numbers of cells with reduced size (reduced FSC) increase in a
time-dependent manner. In plots, CLL cells untreated (Control) or incubated with CD47 mAb (1 h) were measured, quantified, and plot-
ted as a percentage of total cells. CD47 mAb-treated cells were divided into two groups according to their size: G1 = similar size to
untreated cells (46% total cell population); G2 = cells with reduced diameter (54% of total cell population). Cell size was measured in
150 untreated cells and 150 CD47 mAb-treated CLL cells. Data are the means ± SD of five independent experiments. *p < 0.01,
unpaired Student’s t test. (F) Assessment of cell death in CLL cells pre-incubated (30 min) with pan-caspase-inhibitors QVD or z-VAD.fmk,
or specific inhibitors of caspase-3 and -7 (z-DEVD.fmk), -8 and -10 (z-IETD.fmk), or -9 (z-LEHD.fmk) before induction of death by CD47
mAb (1 h). Results are the means of five independent experiments ± SD. (G) B lymphocytes from a representative CLL donor were left
untreated (Control), or incubated with CD47 mAb (1 h) or CD47 mAb + TPCK (20 µM), before assessment of chymotrypsin-like serine
protease activity with a green fluorescent SerPase kit (FFCK). Note that CD47 triggering provokes positive staining and that TPCK
inhibits serpase labeling. Numbers indicate the percentage of cells positively stained. The experiment was repeated four times with a
lower variability (<5%). (H) B-lymphocytes from 20 CLL patients (see Table 1) were cultured for 1 h in the presence of CD47 mAb (cir-
cles) or 20 h in the presence of the apoptotic inducer HC (squares). The percentage of annexin V+ cells is shown. Median values are
shown as black bars. B-cells were divided into two groups according to their relative sensitivity to CD47 mAb and HC (see Results sec-
tion for details). Right histogram: Bcl-2 and Bax mRNA ratios obtained from healthy (B cell) or CLL B lymphocytes from the two groups
defined above. Results are expressed as the mean ± S.E.M.
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diate filaments. In untreated CLL cells, the actin network
appeared as a fluorescence surrounding the nucleus with a
homogeneous distribution, the tubulin network as tubular
structures at the periphery of the nucleus, and the
vimentin network as uniformly distributed punctuate
structures (Figure 2A). CD47 ligation selectively induced a
change in actin microfilaments, which were then repre-
sented by a discontinuous pattern and formation of actin
aggregates (Figure 2A). The other two networks, micro-
tubules (e.g., tubulin) and intermediate filaments (e.g.,
vimentin), remained undisturbed or only slightly modified
(Figure 2A). In a first attempt to quantify these alterations
in the cytoskeletal pattern, we measured fluorescence
intensity in untreated and anti-CD47 monoclonal anti-
body-treated CLL cells (Figure 2A). Total fluorescence
intensity in the actin network was 490±33 in untreated
cells and 248±28 in the CLL-treated cells of reduced size
(49% loss of fluorescence). With regards to the tubulin net-
work, total fluorescence intensity in untreated cells was
454±28, and 440±30 in CLL-treated cells. For the interme-
diate filaments, total fluorescence intensity was 727±36 in
untreated cells and 750±46 in CD47-treated cells. Thus,
after CD47 ligation, the morphological modifications
detected in the actin cytoskeleton were accompanied by a
relevant loss in fluorescence intensity. As observed by the
absence of alterations in tubulin and intermediate fila-
ments, fluorescence intensity remained unchanged.
Additional evidence of the morphological changes induced
by CD47 triggering in the actin microfilaments was found
using a three-dimensional-reconstruction-based assay
(Figure 2B and Supplementary Movies 1 to 6). This approach,
in which we Z-scanned the entire CLL cell, fully corrobo-
rated the discontinuous pattern and the formation of actin
aggregates in CLL cells after CD47 triggering.
Actin microfilament rearrangements control
CD47-mediated type III programmed cell death
The morphological changes observed in the cytoskele-
ton of CD47-treated cells led us to evaluate a possible role
of this cellular compartment in the regulation of CD47-
mediated PCD. A pharmacological analysis demonstrated
that actin-dynamic inhibitors such as cytochalasin D or
latrunculin A precluded CD47 PCD, while microtubule-
interfering agents (e.g., nocodazole, colchicine or taxol) or
inhibitors of intermediate filament dynamics (e.g., okadaïc
acid) failed to modulate this kind of death (Figure 3A). In
the same way, pre-treatment of CLL cells with cytocha-
lasin D eliminated the mitochondrial morphological
changes induced by CD47 triggering (Figure 3B). A similar
outcome was observed in the entire set of CLL patients
described in Figure 1H. Overall, these data reveal a new
role for the actin cytoskeleton network in controlling type
III PCD.
This important result led us to further characterize this
network in type III PCD. We first measured the intracellu-
lar F/G-actin ratio (F = fibrillar = polymerized-actin; G =
globular = depolymerized-actin)23 at time intervals in cells
treated with TSP-1 or anti-CD47 monoclonal antibody.
This approach showed that the F/G-actin ratio decreased
in a time-dependent manner with similar kinetics to
CD47-mediated death, indicating that CD47 ligation pro-
voked actin depolymerization (Figure 3C). Strikingly, we
demonstrated that CD47 triggering not only induced F-
actin disruption but also actin degradation (Figure 3D).
This certainly explains the loss of fluorescence intensity in
the actin cytoskeleton of CD47-treated cells (Figure 2).
Interestingly, inhibition of the actin dynamics or blockage
of the serpases by TPCK controlled both actin damage and
degradation (Figure 3D). Thus, it seems that this family of
serine proteases regulates CD47-mediated PCD upstream
of the actin cytoskeleton.
Hierarchical relationship between serpases,
F-actin damage, and mitochondria in CD47-mediated
programmed cell death
The serpase-dependent actin injury depicted in Figure 3
has revealed a new role for this family of proteases and F-
actin in controlling type III PCD. Indeed, together with
our previous results,17 our new data strongly suggest a
Figure 2. CD47 ligation specifically provokes actin microfilament
rearrangements: evidence from fluorescence quantification and
3D-reconstruction. (A) CLL cells were cultured in the absence
(Control) or presence of CD47 monoclonal antibody (mAb) for 1 h,
and subjected to immunofluorescent detection of actin-microfila-
ments (actin), microtubules (tubulin), and intermediate filaments
(vimentin). Representative micrographs of each stain are shown.
Individual cells are representative of the dominant phenotype.
Plots depict the statistical analysis of total fluorescence. Bar = 8
µm. This experiment was repeated eight times, yielding compara-
ble results. *, (p < 0.01, unpaired Student’s t test). (B) 3D-recon-
struction of CLL cells cultured in the absence (Control) or presence
of CD47 mAb as in (a), and subjected to confocal assessment of
actin, tubulin, and vimentin. 3D-micrographs for the dominant
phenotype of each cytoskeleton stain are shown. The same cell is
represented in the absence (left panel)/presence (right panel) of
nucleus. Blue = Hoestch 33342 nuclear staining, green = specific
network labeled. The experiment was repeated four times with
low variability. 
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hierarchical relationship between serpases, F-actin dam-
age, and mitochondria in this PCD program. To verify
this possibility and to determine the sequence of events
characterizing CD47-mediated PCD, we used a cytofluo-
rimetric approach. Our working hypothesis was that the
serine proteases are activated shortly after CD47 trigger-
ing, and before F-actin damage and the mitochondrial
alterations representing this type of PCD. We, therefore,
chose a suitable time frame (5 to 60 min) to evaluate ser-
pase activation and the modifications in the actin net-
work, and comparatively analyzed CLL cells untreated or
treated with anti-CD47 monoclonal antibody. As shown
in Figure 4A, serpases were activated as soon as 10-15
min after CD47 triggering. Importantly, at this time point,
the actin network still remained undisturbed (Figure 3C).
In fact, actin became disrupted only 30 min after CD47
triggering. These results confirm the activation of serpas-
es at an early pre-cytoskeleton step in CD47-mediated
PCD. In this way, in contrast to TPCK, neither cytocha-
lasin D nor latrunculin A has an influence on serpase acti-
vation (Figure 4A, right panels). However, they inhibit
actin degradation (Figure 3D), ∆Ψm dissipation (Figure
3A), and the morphological changes induced by CD47
triggering in mitochondria (Figure 3B). Therefore we
could propose a sequence of events in which CD47 trig-
gering provokes serpase activation and F-actin rearrange-
ments upstream of the mitochondrial changes character-
izing CD47-mediated PCD.
We next sought to integrate our previously reported
data on Drp117 with the sequence of events described
above. In this context, we showed that Drp1 redistribu-
tion from the cytosol to mitochondria was actin-related,
since pre-treatment of CLL cells with cytochalasin D pre-
cluded the mitochondrial relocation of Drp1 (Figure 4B,
and C). Nocodazole, which does not inhibit mitochondr-
ial damage or type III PCD, also failed to block the mito-
chondrial relocation of the protein (Figure 4C). As expect-
ed, the serpase inhibitor TPCK alleviated Drp1 mitochon-
drial redistribution (Figure 4C).
Altogether, these data reveal a sequence of events in
which, after CD47 ligation, the activation of serpases is
followed by F-actin network disruption, and Drp1 redis-
tribution from the cytosol to mitochondria.
CD47-mediated type III programmed cell death
and cell clearance
Type III PCD has often been viewed as an accidental
and uncontrolled process of PCD.10 In this way, its puta-
tive role in the elimination of tumor cells is poorly under-
stood. However, despite this view of uncontrolled type III
PCD, our results indicate a finely regulated mechanism.
Following these new data, a key question emerged: are
the cells that die by type III PCD recognized and engulfed
by macrophages? To answer this important question, we
monitored whether CD47-treated cells are phagocyted by
macrophages. CLL cells undergoing hydrocortisone
induced (positive control) or CD47-mediated death were
cultured with CD13-labeled macrophages and analyzed
by immunofluorescence and flow cytometry following a
previously described method.24 This analysis indicated
that, like hydrocortisone (a classical type I apoptotic
inducer), CD47-induced type III PCD is an efficient path-
Cytoskeleton rearrangements in type III PCD
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Figure 3. CD47 ligation induces type III PCD via F-actin depolymer-
ization and degradation. (A) ∆Ψm dissipation measured in CLL cells
treated 1 h with CD47 monoclonal antibody (mAb) in the absence
(no inhibitor) or presence of actin-dynamic inhibitors (cytochalasin
D and latrunculin A), microtubule-interfering agents (nocodazole,
colchicine and taxol), or the intermediate filament disassembler,
okadaic acid. Histograms indicate the percentage of cells present-
ing ∆Ψm loss. Data are the mean of five independent experiments
± SD. (B) Electron microscopy views of CLL cells untreated (Control)
or pre-incubated (30 min) with cytochalasin D or nocodazole before
being treated with CD47 mAb (1 h). Representative mitochondrial
micrographs (left panels) show the normal mitochondrial morphol-
ogy observed after cytochalasin D pre-treatment (upper panel). In
contrast, nocodazole did not prevent the mitochondrial modifica-
tions provoked by CD47 triggering (lower panel). MT = mitochon-
dria. (C) CLL cells were exposed to CD47 mAb or TSP-1 at different
times or pretreated with cytochalasin D or TPCK (30 min) before
being treated with CD47 mAb (1 h), and the fluorescence F/G actin
ratio was quantified. One unit refers to the basal F/G actin ratio
scored in untreated cells. Data are the mean of five independent
experiments ± SD. (D) CLL cells were exposed to CD47 mAb at dif-
ferent times or pretreated (30 min) with cytochalasin D, latrunculin
A, or TPCK before being treated with CD47 mAb (1 h), and actin was
analyzed by immunoblotting in total cell extracts. PVDF membrane
was stained with naphtol blue to control protein loading.
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way enabling dying cells to be recognized and engulfed
(Figures 5A and B). Control experiments performed with
caspase and serpase inhibitors, modulators of actin
dynamics, a CD47–/– cell line (JinB8),27 and a double
approach showing that the number of dying cells is strict-
ly related to the number of engulfed cells, all confirmed
that CD47-mediated PCD is an efficient pathway for
eliminating dying cells (Figures 5B and C).
Discussion
Drug resistance limits the effectiveness of existing med-
ical treatments and is a major challenge in the current
research on PCD. In the last few years, PCD-based phar-
macological therapies have been mainly focused on the
apoptosis type I PCD pathway and the main regulators of
this type of cell death (e.g., caspases or the Bcl-2 family of
proteins). Theoretically, modulation of PCD using cas-
pase/Bcl-2 regulators could be an effective treatment for
cancer. Unfortunately, most of these studies are still in the
stage of preclinical development because of the relatively
low efficacy of the agents. This is certainly related to the
resistance developed by tumor cells against type I PCD.
Hence, there is enormous interest in designing new thera-
peutic agents to modulate key molecules involved in non-
apoptotic or caspase-independent PCD pathways.
Emerging knowledge about these death pathways have
revealed new potential strategies for medical therapy. In
this sense, type III PCD is a very promising target in CLL.
On the one hand, our data confirm that it is a general PCD
pathway. On the other hand, this death pathway seems to
be independent of the main apoptotic proteins altered in
CLL, such as Bcl-2, Bcl-XL, Mcl-1, Bax, Bak, or Bim.17
Through a large assessment, we have described here a
newly discovered sequence of events characterizing type
III caspase-independent PCD. Briefly, we have shown that
ligation of the CD47 receptor leads, by means of serpases,
to F-actin injury and the translocation of Drp1 from the
cytosol to mitochondria (Figure 6). Importantly, F-actin
Figure 4. Hierarchical involvement of ser-
ine proteases, F-actin, and Drp1 in CD47-
mediated type III PCD. (A) B-lymphocytes
from a representative CLL donor were left
untreated (Control), or incubated with
CD47 monoclonal antibody (mAb) at dif-
ferent times before assessment of chy-
motrypsin-like serine protease activity with
a SerPase kit as in Figure 1F. Numbers
indicate the percentage of cells positively
stained. The experiment was repeated four
times with a low variability (<5%). In a sim-
ilar experiment, B-lymphocytes from the
same CLL donor were left untreated
(Control) or pretreated with TPCK, cytocha-
lasin D, or latrunculin A 30 min before
being treated with CD47 mAb (1 h).
Numbers indicate the percentage of cells
positively stained. Note that only TPCK
inhibits serine protease activation. The
experiment was repeated three times with
a low interexperimental variability (<5%).
(B) CLL cells were left untreated (Control)
or treated with CD47 mAb for 1 h, and
stained for the detection of Drp1 and
cytochrome c (Cytoch. c, used as a mito-
chondrial marker), before being examined
by fluorescent microscopy. Representative
cells show that Drp1 has a cytosolic distri-
bution in control cells, whereas it co-local-
izes with cytochrome c in CD47-treated
cells. The number of cells presenting posi-
tive annexin V labeling (measured by flow
cytometry), or Drp1/cytochrome c colocal-
ization was quantified and plotted as a
percentage of total cells. Data are the
means ± SD of five independent experi-
ments. (C) Drp1 mitochondrial redeploy-
ment detected by immunoblotting. CLL
cells were left untreated, treated with
CD47 mAb for 1 h, or pre-incubated with
TPCK (20 µM), cytochalasin D, or nocoda-
zole (30 min) before being treated with
CD47 mAb (1 h). Cells were subjected to
subcellular fractionation and mitochondri-
al and cytosolic fractions were blotted for
Drp1 immunodetection. Fractionation
quality and protein loading were verified
by the distribution of the specific subcellu-
lar markers: Cox IV for mitochondria and
tubulin for cytosol.
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rearrangement is a key step in type III PCD. At least three
main observations support this assertion. First, depoly-
merization of the actin network is a constant feature in
this type of PCD. Second, inhibitors of actin dynamics
(e.g., latrunculin A or cytochalasin D) abolish the hall-
marks of this type of PCD (e.g., mitochondrial alterations,
PS exposure, and cell clearance). In contrast, inhibitors of
the other two cytoskeleton networks (e.g., nocodazole or
okadaïc acid) do not prevent type III PCD. Finally, CD47
triggering selectively induces a change in actin microfila-
ments, while the other two networks, microtubules and
intermediate filaments, remain undisturbed. Importantly,
F actin disruption/degradation and the control mediated
by the serpases are essential to an understanding of the
interplay between the multiple type III PCD signals. 
Our results place serpases and cytoskeleton rearrange-
ments at an early pre-mitochondrial step in caspase-inde-
pendent type III PCD and indicate a hierarchical relation-
ship between serpases, F-actin rearrangement, and Drp1
redistribution from the cytosol to mitochondria. A more
specific analysis could now be developed to understand
the relationship between serpases, actin, Drp1, and other
proteins previously implicated in CD47-mediated PCD,
such as WASP,25 protein kinase C θ,28 or protein kinase A.29
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Figure 5. CD47-mediated type III PCD induces cell death clearance. (A) CLL cells were stained in red with PKH26 linker before treat-
ment with hydrocortisone (HC) or CD47 monoclonal antibody (mAb) (1 h). Cells were then cultured for 3 h with U937 cells differentiat-
ed to macrophages at a 1:1 ratio, and the mixture analyzed by immunofluorescence. Cells were stained with Hoeschst 33342 to visu-
alize nuclei and chromatin condensation. Phase contrast was used to localize cells. White arrows mark engulfed CLL cells. (B)
Quantification of CLL cell engulfment. In a similar experiment to (A), CLL cells were left untreated or treated with HC, HC + z-VAD.fmk,
CD47 mAb (1 h), CD47 mAb (1 h) + z-VAD.fmk, or pretreated with cytochalasin D, latrunculin A, or TPCK (20 µM) before being treated
with CD47 mAb for 1 h, and stained with BODIPY® FL C5-Ceramide (green) and macrophages were labeled with anti-CD13-APC antibody
(red). After co-culture, the mixture was analyzed by flow cytometry and the double positive cells (macrophages containing apoptotic cells)
quantified and expressed as a percentage. Values are shown as the mean ± SD (n=6). (C) Relationships between CLL or JinB8 cell engulf-
ment and death. Cells were stained in green with BODIPY® FL C5-Ceramide before being left untreated or treated with CD47 mAb (1 h).
Cells were then cultured with macrophages differentiated from U937 cells labeled with anti-CD13-APC antibody and analyzed as in (B).
Values are shown as the mean ± SD (n=5). Alternatively, cells were labeled with annexin V-APC to assess cell death. The percentage of
annexin V+ cells was recorded and expressed as a histogram. Note that, in contrast to CLL cells, JinB8 (a CD47–/– cell line) cells are resist-
ant to CD47 mAb ligation.
Figure 6. Schematic model for CD47-mediated type III PCD.
Ligation of the CD47 receptor led, by means of the serpases, to F-
actin depolymerization and translocation of dynamin-related pro-
tein 1 (Drp1) from the cytosol to mitochondria, where the protein
induced mitochondrial damage characterized by ∆Ψm collapse,
ROS production, and no release of proapoptotic proteins from the
intermembrane space.17 These alterations are followed by phos-
phatidylserine (PS) externalization and the efficient clearance of
dying cells. Serpase inactivation by TPCK, and actin dynamics mod-
ulation by Cyt D (cytochalasin D), block this PCD pathway. ROS indi-
cates reactive oxygen species; Cyt c cytochrome c; AIF apoptosis
inducing factor; Endo G endonuclease G.
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In this context, it is also interesting to highlight the resem-
blances between CD47 and CD99 cell death programs.
Both receptors induce a rapid caspase-independent PCD
related to actin cytoskeleton dynamics.30
Despite the marked differences characterizing type I
and type III PCD, it is interesting to note that our work
revealed that these two types of death share common bio-
chemical features, namely outer leaflet exposure of PS in
the plasma membrane, alterations to mitochondria, pro-
duction of ROS, and cell engulfment. From the standpoint
of PCD, the common biochemical features in type I and III
PCD indicate that these two pathways leading to cell
death could be different facets of similar PCD processes.
Thus, unraveling the mechanisms governing type III PCD
could lead to a better understanding of PCD in CLL.
Finally, our observations indicated that the CD47/TSP-1
link could play a role in the elimination of tumor cells. TSP-
1, secreted by macrophages and dendritic cells, may con-
tribute to the elimination of tumor cells and even to the
maintenance of immune B-cell homeostasis. Indeed, rapid
recognition and clearance of dying cells by phagocytes play
pivotal roles in the control of immune responses and reso-
lution of inflammation.18,31 Great progress has been made
during the last few years in identifying the molecules on
the surface of type I apoptotic cells, but it is still not clear
how type III PCD dying cells are recognized by
macrophages. It seems that these cells are internalized by a
macropinocytotic mechanism32 and that PS exposure medi-
ates recognition and engulfment. Our data seem to confirm
this assertion and indicate that PS-mediated clearance
could be a general mechanism irrespective of the way a cell
dies. Certainly, the cell death system that we have identi-
fied is an interesting way for deciphering the precise
molecular mechanisms of recognition and phagocytic
uptake of cells killed by caspase-independent apoptosis.
Future goals in research associating CLL and PCD
include the development of therapeutic agents that pro-
voke leukemic cell death. Our experiments, performed in
B cells from 20 CLL patients, show that CD47 ligation
provokes PCD rapidly and with a high efficacy.
Importantly, our molecular data further imply the exis-
tence of a biochemical type III PCD pathway that could be
regulated to target CLL cells. The induction of type III
PCD can, therefore, be used in CLL as a potential means
of bypassing otherwise blocked PCD pathways.
Moreover, in a complementary approach, chemothera-
peutic efficacy could also be improved by combining ther-
apies that target more than one single cell death effector
(e.g. caspases and F-actin).
We can propose four strategies for using type III PCD
and, more specifically, F-actin in the enhancement of the
cell death response in CLL: (i) Based on previous studies
carried out in other cellular systems, a first interesting
therapeutic approach to regulating type III PCD in CLL is
the modulation of F-actin dynamics. For example, addi-
tion of jasplakinolide, a drug that stabilizes the actin
cytoskeleton and induces accumulation of large F-actin
aggregates, increases PCD in human Jurkat T cells and
interleukin-2 (IL-2)-dependent lymphocytes.33 Incubation
of cells with cytochalasin D also modulates PCD in acti-
nomycin-induced cell death.34 Similarly, down-regulation
of the actin protein, gelsolin, stabilizes the actin cytoskele-
ton and regulates apoptosis.33 In this system, treatment
with cytochalasin D protects cells from death. (ii) In addi-
tion to the actin stabilization/depolymerization possibili-
ty, a second approach to regulating F-actin-mediated PCD
is the simple alteration of F- or G-actin status. This is suf-
ficient to induce death.36 (iii) Recent data suggest that alter-
ations in the activity of actin regulatory proteins, such as
coronin, gelsolin, β-thymosins, and cofilin, play crucial
roles in the regulation of PCD in mammals.36 These pro-
teins are potential targets to provoke PCD through F-actin
disruption. (iv) Residing in the F-actin cytoskeleton,37 Drp1
translocated to mitochondria where this protein provoked
death after CD47 triggering.17 This result indicates that the
Drp1-cytoskeleton link was disturbed after CD47-ligation.
Thus, interference in Drp1-cytoskeleton binding could be
used to enhance Drp1 redistribution from the cytoskele-
ton to mitochondria and, consequently, to enhance type
III PCD.38
Given the growing understanding of the complexity of
the PCD phenomenon, it is becoming clear that targeting
only caspase pathways is often not sufficient (or efficient)
for the treatment of diseases with disorders in prolifera-
tion/death equilibrium, such as CLL. A comprehensive
analysis of caspase-independent cell death pathways thus
offers a new challenge in the design of drugs targeting
PCD more broadly. Regarding type III PCD, our results
demonstrated that it is possible to provoke PCD in cells
with a deficient mechanism of apoptotic (type I) cell
destruction. This is good news, implying that specific type
III PCD pathways can be targeted in CLL independently of
classical caspase-dependent apoptotic pathways. This will
certainly help in avoiding ineffective treatments. In any
case, investigating the various cell death cascades will
potentially lead to a deeper understanding of the phys-
iopathology of hematologic diseases, such as chronic lym-
phocytic leukemia.
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